The central premise of the study is that macrophages and monocytes inside tumors exist in a continuum of functional states that cannot be reduced to a single binary. To quantify this continuum, the researchers built the MDRi around three core programs: an injury program capturing stress responses such as iron and heme handling, hypoxia, inflammatory chemokines and danger-sensing pathways; a resolution program reflecting tissue repair, efferocytosis, lipid processing and resident-like macrophage biology; and a combined antigen-presentation and interferon program, abbreviated APC/IFN, that brings together major histocompatibility complex activity and interferon-stimulated genes. From the injury and resolution programs they also derived an injury-resolution axis, a single metric that places each cell along a spectrum from active damage to active healing.

Constructing and validating a framework of this kind required an unusually broad evidence base. The team established MDRi in an immune checkpoint blockade-treated multi-cancer atlas containing 47,750 myeloid cells drawn from 192 samples spanning eight cancer types. They then tested the framework separately in an independent multi-cancer myeloid dataset to confirm that the identified programs were not artifacts of a particular cohort or sequencing batch. Because the antigen-presentation and interferon-response gene sets were deliberately constructed to be non-overlapping, agreement between these two signatures provided gene-independent support for the validity of the APC/IFN dimension, an important safeguard against circular reasoning in signature-based immunology.

One of the more technically interesting aspects of the study concerns the geometry of myeloid cell states. Using trajectory inference, the researchers found that macrophage and monocyte states organized along related but non-identical functional dimensions, and root-sensitivity analyses revealed a subtle but important caveat: the connectivity of the states was stable regardless of where the trajectory was anchored, but the inferred directionality of pseudotime depended on the choice of root. The authors interpret this as evidence that MDRi captures genuine transcriptional topology rather than a universal developmental sequence, a deliberately cautious conclusion that resists over-interpreting pseudotime as a maturation timeline in tumor myeloid biology.

The framework was then put to the test against clinical data. In exploratory analyses of checkpoint blockade-treated patients, the researchers observed that post-treatment non-responders showed concurrent elevation of injury, resolution and APC/IFN scores, suggesting a globally activated but functionally ambivalent myeloid compartment. However, when the analyses were adjusted for cancer type and treatment regimen, the data did not support an independent predictive effect of MDRi scores on response. Complementary analyses of T and natural killer cells indicated that immune differences associated with treatment response were actually more evident in pretreatment samples, hinting that the pretreatment immune landscape, rather than treatment-induced myeloid changes, may carry the stronger predictive signal.

Prognostic analysis in bulk tumor data added another layer of context dependence. The researchers projected MDRi programs onto patient-level cohorts from The Cancer Genome Atlas and fitted joint multivariable Cox models containing the injury, resolution and APC/IFN scores. The derived injury-resolution axis was excluded from these joint models because it is mathematically dependent on its two components, a statistically transparent choice. The results showed MDR injury acting as an adverse factor in selected cancers, while resolution and APC/IFN displayed associations that varied by cancer type and clinical endpoint. In other words, the same myeloid program can be associated with better outcomes in one tumor type and worse outcomes in another, which is precisely the kind of context dependence the framework was designed to expose.

Because single-cell atlases are far less common than bulk transcriptomic cohorts, a framework is only as useful as its portability. The researchers benchmarked MDRi against established immune-deconvolution methods such as MCP-counter, TIMER and xCell, as well as against published tumor-associated macrophage signatures. The comparison demonstrated partial but non-uniform overlap, meaning that MDRi captures myeloid-state information that is related to, but not fully explained by, conventional deconvolution scores. This positions the index as a complementary rather than redundant measurement, adding functional granularity that abundance-based methods cannot provide.

The spatial dimension of myeloid biology received particular attention. Using Visium spatial transcriptomics in nasopharyngeal carcinoma, the team mapped MDRi programs onto hematoxylin and eosin stained tissue sections, revealing that injury, resolution and APC/IFN programs occupy focal tissue niches rather than being uniformly distributed. A parallel multi-cancer Xenium analysis at single-cell spatial resolution across cervical cancer, glioblastoma, lung cancer and melanoma further revealed platform- and cancer-dependent spatial distributions of the MDRi-related programs, including cancer-specific estimates of how APC/IFN-high myeloid cells position themselves near tumor cells and how checkpoint interactions vary in their vicinity. These findings suggest that the functional identity of myeloid cells is shaped not only by cancer type but by precise anatomical microenvironment.

To make the framework accessible, the researchers released MDRi Explorer, an open-source Shiny application that implements scoring, reference comparison, survival analysis and benchmark visualization. Users can apply MDRi to their own transcriptomic data, compare their results against built-in references, and explore cancer-specific score distributions and survival associations from TCGA. The authors are careful to frame the contribution appropriately: MDRi is presented as a reusable, hypothesis-generating framework for investigating context-dependent myeloid functional organization, not as a universal prognostic signature or a clinically validated predictor. That restraint is notable in a field where signature-based tools are often oversold.

The broader significance of the work lies in its refusal to flatten myeloid biology into a single number. By decomposing the tumor myeloid compartment into injury, resolution and antigen-presentation/interferon dimensions, and by documenting honestly where those dimensions matter, where they do not, and how their meaning shifts across cancers, platforms and treatment settings, the study provides the immunology community with a map that is as much about uncertainty as about discovery. For researchers designing myeloid-targeted therapies, the message is that the same cell population may be a friend in one tumor and an enemy in another, and that any intervention must be interpreted against the local context of tissue damage, repair and antigen presentation.

Subject of Research: A single-cell-derived myeloid damage response index quantifying context-dependent myeloid functional states across cancers

Article Title: A single-cell-informed framework maps context-dependent myeloid damage-response states across cancers

Article References: Ding, R., Zheng, W., Long, Z., Cao, Z., Liang, J., & Quan, Q. (2026). A single-cell-informed framework maps context-dependent myeloid damage-response states across cancers. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04543-4

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04543-4

Keywords: tumor-associated macrophages, myeloid cells, single-cell RNA sequencing, spatial transcriptomics, pan-cancer, immune checkpoint blockade, immune deconvolution, antigen presentation, interferon signaling, TCGA, myeloid damage response index, tumor microenvironment

The new study, published in the Journal of Experimental & Clinical Cancer Research, focuses on the tumor microenvironment — the dense, inflammatory ecosystem that surrounds and permeates a tumor. Triple-negative breast cancer is notorious for heavy infiltration by myeloid immune cells, including tumor-associated macrophages. For years, these inflammatory macrophages have been statistically linked to poor outcomes, but the precise molecular choreography by which they drive malignant behavior has remained obscure. The Milan-led team, led by senior author Paola Falletta together with co-senior author Carlo Tacchetti, set out to close that gap, and in doing so identified a signaling axis that could become a therapeutic target in one of oncology’s hardest terrains.

The pathway at the center of the discovery is the Integrated Stress Response, or ISR, an ancient cellular circuit that acts as a molecular alarm system. When a cell perceives stress — nutrient deprivation, viral infection, or chemical insults — protein production in the endoplasmic reticulum stalls through phosphorylation of the translation initiation factor eIF2α, and the cell pivots from growth to survival mode, reprogramming gene expression to cope. Normally, this response protects cells. In cancer, however, tumor cells can hijack the ISR to survive hostile conditions, adopt invasive behaviors, and evade cell death. The new work shows that in triple-negative breast cancer, the stress being integrated is not only environmental — it is delivered by the immune system itself.

The researchers combined patient transcriptomic analyses, laboratory functional assays and in vivo metastasis models to build their case. First, mining breast cancer clinical cohorts, they found that gene-expression programs reflecting ISR activation are markedly enriched in triple-negative tumors compared with other breast cancer subtypes. Crucially, the enrichment was not random: high ISR signatures correlated with both poor patient outcomes and the presence of inflammatory macrophage infiltration. That correlation posed an obvious question — were the macrophages merely bystanders, or were they actively switching on the stress programs inside tumor cells?

To test causality, the team turned to controlled experiments in the laboratory. When triple-negative breast cancer cells were exposed to the secretome — the collected cocktail of secreted factors — from inflammatory macrophages, the tumor cells underwent a striking transformation. They activated their ISR circuitry and simultaneously acquired invasive capabilities, pushing through three-dimensional matrices in ways that untreated cells did not. Blocking the ISR pharmacologically or genetically prevented this invasion, demonstrating that the stress response was not a byproduct of the inflammatory exposure but a necessary engine of the invasive switch.

The hunt then turned to identifying which molecule within the macrophage secretion was responsible. Using an approach that combined unbiased screening with targeted validation, the researchers pinpointed CXCL10, a chemokine — a small signaling protein best known for recruiting immune cells to sites of inflammation. The result was remarkable in its completeness: CXCL10 alone was both necessary and sufficient to trigger ISR activation and invasion in the tumor cells. Its effects were mediated through its cognate receptor, CXCR3, displayed on the surface of the cancer cells. In other words, the team had mapped a complete paracrine circuit — macrophages release CXCL10, CXCL10 engages CXCR3 on tumor cells, and the engagement ignites the Integrated Stress Response, converting relatively dormant cancer cells into invasive, metastasis-competent ones.

The final and most demanding piece of evidence came from living systems. Using mouse models of metastatic dissemination, the investigators showed that tumor-intrinsic ISR signaling actively promotes the spread of triple-negative breast cancer in vivo. When the pathway was disrupted, metastatic colonization was impaired. Together, the clinical correlation, the mechanistic dissection and the animal data converge on a single coherent model that the authors describe as the macrophage–CXCL10–CXCR3–ISR axis — a signaling relay that translates inflammation into metastatic competence.

What makes the finding conceptually significant is how it bridges two grand themes in cancer biology that have often been studied in isolation. On one side is inflammation: the long-standing observation that tumors are wounds that never heal, festering in a soup of cytokines and immune cells whose net effect can be pro-tumor. On the other side is cell-intrinsic stress biology: the internal machinery by which individual cancer cells adapt, survive and change identity. By showing that a macrophage-derived chemokine directly engages a core cellular stress pathway to unlock metastatic behavior, the study draws a straight mechanistic line between the immune microenvironment and the plasticity of the tumor cell itself. It suggests that some of the aggressiveness of triple-negative breast cancer is not written into the cancer cells’ own mutations alone, but is coached into them by their inflammatory surroundings.

There are also therapeutic implications, and they are potentially substantial. Each node of the identified axis offers a distinct point of intervention. Inhibiting the ISR in tumor cells, antagonizing CXCR3 with targeted drugs, or neutralizing CXCL10 could each, in principle, sever the signal that converts inflammation into invasion. The finding may also help refine immunotherapy strategies: in tumors dominated by inflammatory macrophages, merely reactivating anti-cancer T cells may not suffice if macrophages are simultaneously priming tumor cells for dissemination. Interventions that reprogram or deplete pro-metastatic macrophages could complement existing immune checkpoint approaches. The authors caution, as with any preclinical discovery, that the road from mouse models and cell culture to safe, effective clinical protocols is long, but they frame the axis explicitly as a potential node for therapeutic intervention, and the pharmacological tools to test that proposition already exist in early development.

For the roughly 10 to 15 percent of breast cancer patients diagnosed with the triple-negative subtype, such prospects matter enormously. The disease disproportionately affects younger women and carries a higher burden in certain populations, and metastatic recurrence — the process this study illuminates — remains the leading cause of death. A molecular signature combining ISR activation and macrophage infiltration could also serve as a prognostic marker, helping clinicians identify which patients harbor tumors primed for spread and might benefit most from intensified surveillance or adjuvant strategies. The research was supported by the Italian Ministry of University and Research, AIRC, the Italian Ministry of Health and the European Union’s NextGenerationEU program, and the authors declare no competing interests. As the field moves toward testing ISR and chemokine-axis inhibitors in solid tumors, this study provides both the rationale and the map: a precise, testable circuit through which the immune system’s own inflammatory soldiers are co-opted to arm the enemy.

Subject of Research: How inflammatory macrophage-derived CXCL10 activates the Integrated Stress Response in triple-negative breast cancer cells to drive metastasis.

Article Title: Inflammatory macrophages promote metastatic potential in Triple-negative Breast Cancer through Integrated Stress Response signaling

Article References: Crippa, M., Salemme, V., Chauhan, J., Colombo, E., Loffreda, A., Lamolinara, A., Cardella, C., Leone, M., Licari, E., Gaviraghi, M., Genova, F., Anselmo, A., Mazza, D., Iezzi, M., R Goding, C., Defilippi, P., Tacchetti, C., & Falletta, P. (2026). Inflammatory macrophages promote metastatic potential in Triple-negative Breast Cancer through Integrated Stress Response signaling. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03821-4

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03821-4

Keywords: triple-negative breast cancer, macrophages, integrated stress response, CXCL10, CXCR3, metastasis, tumor microenvironment, inflammation, cancer research, immunotherapy, tumor-associated macrophages, Inflammatory

The research team, led by Yi Zheng, Qianrong Wang, Qiong Zhang, and Hong-Mei Zhang of the Department of Clinical Oncology at Xijing Hospital, The Fourth Military Medical University in Xi’an, China, retrieved publications from the Web of Science Core Collection covering January 1, 2017 through December 31, 2025. After rigorous screening that excluded purely technical papers, early-access items, and retracted publications, 979 studies—933 articles and 46 reviews—formed the analytical core. These publications, spread across 267 journals and authored by 7,509 researchers, collectively cited 33,183 references, a testament to the field’s rapid expansion and deep intellectual roots.

The analytical toolkit itself reflects the computational sophistication that single-cell biology now demands. The team employed Bibliometrix 5.0 to chart publication and citation trends, CiteSpace 6.1R6 for keyword evolution and interdisciplinary knowledge mapping, and VOSviewer 1.6.20 for constructing co-authorship and collaboration networks, supplemented by R and Python for visualization. Keyword synonyms were manually standardized—merging terms such as hepatocellular carcinoma, HCC, and liver cancer into unified categories—while dual-map overlays traced how knowledge flows between research domains, revealing citation trajectories from molecular biology and immunology into genetics, and from clinical medicine into health sciences.

The headline finding is a dramatic acceleration in output. Publications and citations rose steeply between 2017 and 2020 before continuing upward at a more moderate pace, a trajectory the authors characterize as typical of an emerging field transitioning from early adoption to maturity. Geographically, the landscape is strikingly concentrated: China leads in both publication volume and citations, amassing 12,576 citations compared with 2,689 for the United States and 1,073 for France. Even more remarkable, all ten of the most prolific institutions are Chinese, with Fudan University alone producing 287 articles—29.3 percent of the total—followed by Sun Yat-sen University with 192 and Zhejiang University with 139. The United States remains China’s primary international partner, anchoring a powerful trans-Pacific research axis, while secondary collaborations link Japan with Canada, Australia with Germany, and Spain with Italy.

Within China, the analysis uncovered a pronounced regional imbalance. Research activity clusters in the southeastern coastal and central regions—Shanghai, Guangdong, Zhejiang, and Hunan—while western and northeastern provinces contribute far fewer studies. The authors attribute this pattern to two interlocking factors: the endemicity of hepatitis B virus in southeastern China, which drives a correspondingly high liver cancer burden and attracts greater funding, and the uneven distribution of biomedical research infrastructure. This concentration underscores, they argue, the need for intranational collaborative networks that connect established hubs with high-burden regions that have historically lacked research capacity.

At the individual level, a small cadre of investigators anchors the field. Fan Jia emerges as the most prolific contributor with 25 publications, followed by Zhou Jian with 24 and Gao Qiang with 12, and these same researchers serve as central hubs in the co-authorship network, connecting multiple research groups. Among the most cited authors, Zhang Zemin leads with 3,187 citations, ahead of Zhang Mingqi with 3,138 and Hu Xuedan with 1,217. The journal landscape is equally revealing: Frontiers in Immunology published the most articles at 80, while Cell accumulated the highest citation count at 2,174, followed by the Journal of Hepatology with 2,016 and Nature with 1,495. Core journals fostering collaboration include the Journal of Hepatology, Nature Communications, and Frontiers in Immunology.

The intellectual foundations of the field trace back to a handful of landmark studies. The most cited publication, with 1,558 citations, is the 2017 Cell paper by Zheng and colleagues, ‘Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing,’ which established the first comprehensive single-cell transcriptomic atlas of T cells in hepatocellular carcinoma and exposed the profound heterogeneity and dysfunctional states of tumor-infiltrating immune cells. The second most cited work, Zhang and colleagues’ 2019 Cell study on the dynamic immune landscape of hepatocellular carcinoma, identified LAMP3-positive dendritic cells as migratory regulators of lymphocyte crosstalk. Aizarani and colleagues’ 2019 Nature paper, which constructed a comprehensive human liver cell atlas and discovered a TROP2-intermediate progenitor population with bipotent organoid-forming capacity, rounds out the foundational trio. Co-citation analysis further shows the field rests on a dual foundation: deep exploration of cancer-associated fibroblasts and stromal biology, exemplified by a heavily cited 2017 Annual Review of Pathology review, coupled with adoption of key computational tools such as SCENIC, the single-cell regulatory network inference and clustering method published in Nature Methods.

Perhaps the most compelling narrative emerges from the keyword evolution analysis, which documents a clear three-phase conceptual progression. The initial phase was descriptive, dominated by terms like gene expression, intratumor heterogeneity, and transcriptome, as researchers cataloged the complete cellular repertoire of liver tumors and identified previously unappreciated malignant subpopulations with stem-like properties. The second phase shifted to the tumor microenvironment, with surging interest in T cells, macrophages, cancer-associated fibroblasts, and immunosuppression—work that dismantled the simplistic M1/M2 macrophage dichotomy and revealed exhausted CD8-positive T cells and regulatory T cells as drivers of immune evasion. The current frontier, marked by burst keywords including cellular crosstalk, growth factors, extracellular vesicles, and gene regulatory networks, moves from static snapshots to dynamic models of intercellular communication, as computational tools infer ligand-receptor interactions and map the signaling circuits that orchestrate angiogenesis, metastasis, and drug resistance.

These insights are already flowing into clinical translation. Single-cell RNA sequencing has refined the understanding of immune checkpoints beyond PD-1, revealing co-inhibitory and co-stimulatory receptors on specific T cell subsets and paving the way for rational combination immunotherapies, such as TIGIT and PD-1 co-blockade. The identification of pro-tumorigenic myeloid populations, including TREM2-positive macrophages that suppress CD8-positive T cell infiltration after transarterial chemoembolization, has opened targets for myeloid-directed therapies such as CSF1R and CD47 blockers. Distinct cancer-associated fibroblast subtypes, some of which determine immunotherapy efficacy—such as POSTN-positive fibroblasts—can now be selectively targeted or reprogrammed, with FAP inhibitors advancing through clinical testing for advanced solid cancers. The technology has also exposed vulnerabilities in therapy-resistant subclones: targeting PPAR-gamma counteracts tumor adaptation to immune checkpoint blockade, while the SNRPB-CCNB1 axis, which promotes progression and cisplatin resistance through lipid metabolism reprogramming, offers a route to augment chemotherapy sensitivity. Cell-type-specific gene signatures derived from single-cell data can deconvolve bulk RNA sequencing from patient biopsies, yielding prognostic tools such as a senescence-related gene signature and a 57-gene matrix stiffness signature that aid patient stratification and personalized treatment planning.

The authors are candid about the field’s remaining obstacles. Tissue dissociation of fibrotic livers can introduce transcriptional stress artifacts, and the loss of spatial context limits interpretation of cellular interactions. Batch effects across datasets and the sheer dimensionality of single-cell data complicate integration and noise discrimination, while high costs restrict large-scale cohort studies and the absence of standardized protocols hampers reproducibility. Emerging solutions—spatial transcriptomics, fixed-cell technologies, and machine learning-based batch correction—begin to address these limitations. The bibliometric analysis itself carries caveats: reliance on a single English-language database may underrepresent non-English contributions, and citation counts do not necessarily reflect clinical significance. Notably, the dual-map overlay revealed sparse representation from the physics, materials, and chemistry domains, suggesting untapped potential for interdisciplinary integration. Looking forward, the authors call for accelerated functional validation of single-cell-identified targets in preclinical models, standardized computational pipelines for inferring intercellular communication networks, and dedicated funding programs to broaden access. What began as cellular cartography, the analysis concludes, has evolved into a sophisticated discipline deconstructing the dynamic tumor ecosystem—one that offers a clear path toward more personalized and effective therapies for a disease that urgently needs them.

Subject of Research: Bibliometric analysis of single-cell RNA sequencing research in liver cancer

Article Title: Bibliometric analysis of research on liver cancer and single‑cell RNA sequencing: evolutionary trends, opportunities, and future perspectives

Article References: Zheng, Y., Wang, Q., Zhang, Q., & Zhang, H.-M. (2026). Bibliometric analysis of research on liver cancer and single‑cell RNA sequencing: evolutionary trends, opportunities, and future perspectives. Holistic Integrative Oncology, 5(1), Article 65. https://doi.org/10.1007/s44178-026-00285-6

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00285-6

Keywords: single-cell RNA sequencing, liver cancer, hepatocellular carcinoma, tumor microenvironment, bibliometric analysis, cancer-associated fibroblasts, tumor-associated macrophages, gene regulatory networks, immunotherapy, spatial transcriptomics, cellular crosstalk, biomarkers

The central concept guiding this research is the tumor microenvironment, or TME, the scaffold of extracellular matrix within which tumor cells and host immune cells communicate and compete. Many cancers are described as immunologically cold, meaning they contain few functional cytotoxic immune cells and resist the effects of immune checkpoint inhibitors, the landmark therapies that block inhibitory receptors such as PD-1 and PD-L1 to unleash CD8-positive T cells. Checkpoint inhibitors have transformed survival for many patients since emerging in the 1990s, but their efficacy is throttled by features of the TME, including low T cell numbers, T cell exhaustion, oxygen-starved tissue, and dense populations of immunosuppressive cells. The review’s authors, led by Campbell M. Johnston and Hongji Zhang of the University of Virginia’s Department of Surgery, argue that exercise directly counters many of these barriers, effectively warming cold tumors and sensitizing them to drugs that were previously powerless against them.

One of the most detailed lines of evidence concerns tumor-associated macrophages, or TAMs, immune cells that are abundant within cold tumors and frequently promote malignancy. TAMs exist along a spectrum from the M1 phenotype, which fights tumors, to the M2 phenotype, which secretes immunosuppressive molecules such as interleukin-4, interleukin-10, PD-L1, and transforming growth factor-beta that blunt effector T cell function and empower regulatory T cells. Worse, TAMs can push CD8-positive T cells into a terminally exhausted state from which they cannot recover, and hypoxia accelerates this process. In mouse models of glioblastoma, depleting TAMs increased the proportion of stem-like progenitor-exhausted T cells and improved responsiveness to anti-PD-1 therapy, underscoring how central these cells are to treatment failure. Preclinical studies now show that aerobic exercise can tip the balance, repolarizing macrophages from the pro-tumor M2 state toward the anti-tumor M1 state and reducing total M2 numbers within tumors.

The macrophage data are remarkably consistent across exercise modalities. Breast cancer-bearing mice that ran on treadmills before and after tumor inoculation showed fewer M2 macrophages within their tumors, while medium-intensity treadmill running increased the M1-to-M2 ratio in similar models. In melanoma-inoculated mice, swimming prevented M2 polarization and reduced interleukin-6 production, inhibiting tumor glycolysis and lowering lactic acid accumulation. Exercise also increased the production of major histocompatibility complex class II molecules on macrophages, sharpening their ability to activate T cells. These findings matter clinically because pharmacological strategies targeting macrophage biology, including inhibitors of transforming growth factor-beta, have struggled in human trials, failing to show clear benefit or producing severe adverse events. Exercise, by contrast, achieves a similar biological reprogramming without toxicity, offering a route around a therapeutic bottleneck that has frustrated drug developers.

Myeloid-derived suppressor cells, or MDSCs, represent a second immunosuppressive population that exercise appears to tame. These cells promote immune evasion by impairing chemokine secretion, recruiting regulatory T cells, and increasing PD-1 expression on T cells. Multiple preclinical studies show that physical activity delays MDSC accumulation and reduces their numbers within tumors. Mice exercised before and after breast carcinoma inoculation had significantly lower intratumoral MDSC levels than sedentary controls, and treadmill running started after tumor inoculation reduced splenic MDSCs, slowed tumor progression, and increased immune cell infiltration in mammary carcinoma models, with an inverse relationship between MDSC abundance and CD8-positive T cell presence. Crucially, these findings extend to humans. In newly diagnosed breast cancer patients, a single session of acute exercise increased natural killer and CD8-positive T cell levels while reducing MDSCs. In esophageal cancer patients who exercised during neoadjuvant chemotherapy, CD8-positive T cell counts rose while inflammatory biomarkers associated with MDSCs and TAMs fell significantly.

Hypoxia and disordered blood vessel growth form a third pillar of the exercise-immunotherapy connection. Tumors grow so erratically that their vasculature becomes tangled and inefficient, starving tissue of oxygen and stabilizing hypoxia-inducible factors that drive further abnormal angiogenesis. The resulting hypoxic environment excludes natural killer and CD8-positive T cells, inhibits dendritic cells and antigen presentation, recruits immunosuppressive cells, and pushes macrophages toward the pro-tumor M2 phenotype through a CXCL8-interleukin-10 signaling axis, all of which correlate with poor prognosis and resistance to checkpoint blockade. Exercise directly counters this vicious cycle. Melanoma-bearing mice that swam at low or moderate intensity showed significantly reduced expression of hypoxia and glycolysis genes, along with greater CD8-positive T cell infiltration and cytotoxicity. Daily high-intensity exercise lowered intratumoral hypoxic fractions in breast carcinoma models, and in a landmark clinical observation, pancreatic cancer patients who exercised during preoperative therapy showed increased tumor vascularity, while exercised mice bearing patient-derived pancreatic tumors displayed vascular remodeling, accelerated regression, and delayed regrowth.

Natural killer cells, the innate immune system’s front-line tumor killers, emerge as perhaps the cells most responsive to exercise. NK cells mobilize more readily into tumors in exercised animals, and work by Cho and colleagues showed that NK cells from exercised individuals kill target cells more efficiently, with their cytotoxicity actually enhanced under hypoxic conditions, a striking advantage given the oxygen-poor nature of tumors. This resilience stems from exercise-induced metabolic reprogramming that reduces mitochondrial oxidative stress and, through interleukin-15 signaling, lessens sensitivity to reactive oxygen species such as hydrogen peroxide within the tumor microenvironment. Clinical translation is already visible: men with localized prostate cancer who adhered strictly to high-intensity interval training showed significantly increased NK cell infiltration into their tumors. Perhaps most dramatic, Pedersen and colleagues found that voluntary wheel running reduced tumor volume by 66 percent in mice lacking functional T cells, an effect abolished when NK cell production was blocked, proving that NK cells alone can mediate exercise-driven tumor suppression.

CD8-positive T cells, the primary targets of checkpoint inhibitors, are recruited into exercised tumors through well-defined molecular routes. The chemokine receptor CXCR3, which binds CXCL9, CXCL10, and CXCL11, guides these cells into tumor tissue, and CXCR3 knockout mice show reduced T cell infiltration and blunted responses to PD-1 blockade. Recent work demonstrated that four weeks of preoperative treadmill running increased CXCL9 release and CXCR3-positive T cell recruitment in colorectal liver metastases, an effect lost in CXCL9-deficient mice. Exercise also suppresses CCL5, a chemokine that recruits regulatory T cells, TAMs, and MDSCs and correlates with poor prognosis, while boosting interleukin-15, a cytokine essential for T cell survival that appears to actively shift CD8-positive cells from circulation into tumors rather than merely raising their blood counts.

The combination studies provide the most compelling case. Melanoma-bearing mice treated with exercise plus anti-PD-1 therapy developed smaller tumors with more apoptotic cells, more cytotoxic T cells, and fewer regulatory T cells than mice receiving the drug alone. Similar synergy appeared in triple-negative breast cancer, where treadmill running improved therapeutic response, boosted T cell and NK cell activation, and cut MDSC numbers alongside anti-PD-1 treatment. In transgenic breast cancer models, adding running to anti-PD-1 therapy delayed tumor growth and improved control, even when both interventions began only after tumors reached a clinically relevant size. Pancreatic ductal adenocarcinoma, notoriously resistant to checkpoint inhibitors, responded to low-intensity treadmill running combined with anti-PD-1 when neither approach worked alone, an especially promising result for patients too ill for vigorous activity. Clinically, hepatocellular carcinoma patients who exercised regularly had significantly better overall and progression-free survival on combined lenvatinib and anti-PD-1 therapy, with matching results in mouse models. Randomized trials such as HI AIM and ERICA are now testing supervised exercise before and during immunotherapy infusions in lung cancer patients.

The authors are careful to note that clinical evidence remains limited and that major questions persist regarding optimal exercise modality, intensity, frequency, timing, and patient selection across cancer types, ages, sexes, disease stages, and body mass indices. Yet the biological coherence of the evidence is difficult to dismiss: exercise relieves hypoxia, normalizes vasculature, repolarizes macrophages, suppresses MDSCs and regulatory T cells, mobilizes NK cells, and drives cytotoxic T cells into tumors through defined chemokine axes, collectively converting cold tumors into inflamed, drug-responsive ones. If ongoing adequately powered trials with longitudinal immune profiling confirm these mechanisms in patients, structured physical activity could become one of the first universally accessible adjuncts to cancer immunotherapy, a prescription written not on a pharmacy pad but into the daily routines of patients fighting some of medicine’s most treatment-resistant cancers.

Subject of Research: How physical exercise modulates the tumor microenvironment to enhance cancer immunotherapy efficacy

Article Title: Physical Exercise in Immunotherapy

Article References: Johnston, C. M., Kim, S. J., Zhang, Y., Tsung, C., Kent, E., May, A., & Zhang, H. (2026). Physical Exercise in Immunotherapy. Sports Medicine – Open, 12(1), Article 130. https://doi.org/10.1186/s40798-026-01101-1

Image Credits: AI Generated

DOI: 10.1186/s40798-026-01101-1

Keywords: physical exercise, cancer immunotherapy, immune checkpoint inhibitors, tumor microenvironment, tumor-associated macrophages, myeloid-derived suppressor cells, natural killer cells, CD8 T cells, PD-1, tumor hypoxia, interleukin-15, cold tumors

One of the most conceptually striking studies targets the tumor microenvironment itself. Researchers developed and evaluated a PET imaging approach aimed at CD163, a surface marker carried by tumor-associated macrophages, the immune cells that tumors frequently recruit and reprogram to support their own growth. In head and neck squamous cell carcinoma, a malignancy in which the immune landscape often determines how patients respond to therapy, a tracer labeled with copper-64, known as 64Cu-ICT-01, allowed investigators to visualize where these macrophages reside and how their distribution shifts during tumor progression and after treatment. Complementary testing on human tissue confirmed that the tracer binds specifically to CD163, supporting its translational relevance. If validated further, the technique could give oncologists a noninvasive window into immunosuppressive niches within tumors, potentially helping predict which patients will benefit from immunotherapy long before changes in tumor size become apparent.

Theranostics, the pairing of diagnostic imaging with targeted radionuclide therapy, features prominently in the new research. A prospective clinical trial evaluated 177Lu-LNC1010, a long-acting somatostatin analog labeled with lutetium-177, for peptide receptor radionuclide therapy in 22 patients with progressive metastatic neuroendocrine tumors. Long-acting formulations are designed to prolong tumor exposure to the therapeutic radiation while simplifying treatment logistics, and in this trial patients received up to four cycles. The investigators systematically assessed safety, tumor response, absorbed radiation doses delivered to tumors and organs at risk, progression-free survival and overall survival during follow-up. The results add to rapidly growing evidence that radioligand therapy can deliver clinically meaningful disease control in neuroendocrine tumors, a class of cancers that has historically been difficult to treat with conventional chemotherapy.

A second radiopharmaceutical study turned its attention to CEACAM5, a cell-surface protein overexpressed in several cancers, including colorectal cancer, and an established target for both antibody-drug conjugates and radioligand therapy. In laboratory and mouse experiments, a radiolabeled compound designed to bind CEACAM5 selectively attached to CEACAM5-positive cancer cells while demonstrating favorable tumor uptake and reduced accumulation in the kidneys, a critical safety consideration for peptide- and antibody-based radionuclide therapies. Remarkably, a single treatment significantly extended survival in mice bearing CEACAM5-positive tumors, with only mild and temporary toxicity observed. The findings position this agent as a candidate for translation into first-in-human trials and reinforce the broader trend of matching radiopharmaceuticals to molecular signatures rather than tumor locations.

Pediatric oncology also gained a potential new target. Neuroblastoma, an aggressive cancer of the sympathetic nervous system that primarily affects young children, remains one of the most challenging malignancies to image and treat. Researchers examined DLL3, a protein better known from small cell lung cancer, as a candidate target in neuroblastoma. Analysis of human tumor samples and preclinical models revealed that DLL3 is widely expressed and frequently localized on the cell surface, an essential prerequisite for both imaging agents and therapeutic radioligands. DLL3-targeted PET imaging subsequently demonstrated tumor-specific uptake not only in preclinical models but also in four patients with relapsed neuroblastoma, offering early clinical proof of concept. For children with few remaining options, a validated DLL3 pathway could open the door to both molecular imaging and precision radioligand therapy in the future.

Beyond theranostics, several new studies interrogate the reliability of the workhorse technology of molecular imaging itself. Amyloid PET, used to detect the amyloid plaques characteristic of Alzheimer’s disease, has become central to diagnosis and to the growing field of disease-modifying Alzheimer’s therapy. A study of nearly 1,500 amyloid PET scans compared interpretations by local radiologists and nuclear medicine physicians with those of expert readers across three FDA-approved tracers. The good news: agreement was consistently strong, with similar performance for positive and negative scans. Importantly, the study also found that lower reader confidence was associated with reduced agreement, suggesting that confidence ratings could serve as a quality-control signal in routine practice. As amyloid PET demand surges worldwide, the findings provide reassurance that community-based interpretation can keep pace with expert standards.

Prostate cancer, the most active arena in nuclear medicine today, received an unusually detailed quantitative treatment. In a multicenter study, researchers evaluated measurements derived from 18F-piflufolastat PSMA PET/CT, matching PET findings with histopathology from 305 men to determine which imaging metrics best distinguish malignant prostate cancer from benign tissue. Several quantitative measures correlated with malignancy, but the SUVmax-to-blood-pool ratio showed the strongest ability to separate cancerous from benign lesions, both within the prostate and at metastatic sites. Establishing such thresholds is a critical step toward standardizing PSMA PET interpretation, reducing unnecessary biopsies, and enabling radiologists to report results with quantitative, reproducible criteria rather than subjective visual assessment alone.

Combination therapy, meanwhile, may soon be guided by a simple blood test and a PET scan. In an analysis of 37 patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617 together with pembrolizumab, an immune checkpoint inhibitor, researchers examined whether baseline biomarkers could predict response. Patients with lower levels of circulating tumor DNA at the start of treatment and higher PSMA uptake on PET fared better, while changes in circulating tumor DNA and PSMA PET measurements at 12 weeks reflected both the depth and durability of response. The study points toward a practical biomarker strategy for selecting patients for combined radioligand immunotherapy, one of the most closely watched approaches in advanced prostate cancer.

Breast and kidney cancer imaging rounded out the new research portfolio. In triple-negative breast cancer, the most aggressive breast cancer subtype, a study compared 18F-ATD001, a PARP-targeted PET tracer, with standard 18F-FDG PET/CT in 37 women. The two methods detected similar numbers of lesions, and although the PARP tracer showed lower overall uptake, its signal correlated moderately with FDG in primary tumors, suggesting it may provide complementary biological information about DNA repair enzyme expression that FDG cannot capture. Separately, a prospective study of 68Ga-DPI-4452, a tracer targeting carbonic anhydrase IX, evaluated 30 adults with suspected kidney tumors. The agent identified clear cell renal cell carcinoma with high sensitivity and detected substantially more metastatic lesions than conventional imaging, with tracer uptake strongly correlating with CAIX expression in tumor tissue, a combination of diagnostic accuracy and biological validation that could reshape renal cancer imaging.

Taken together, the ahead-of-print collection paints a picture of a field in confident ascent. Tracers are becoming more biologically specific, imaging metrics are being quantified against gold-standard pathology, and therapy is increasingly delivered by molecules that home in on cancer cells while sparing healthy tissue. From macrophage mapping in head and neck cancer to DLL3 imaging in children with relapsed neuroblastoma, the studies collectively advance the central promise of nuclear medicine and theranostics: diagnosing and treating each patient according to the unique molecular fingerprint of their disease, with the goal of achieving the best possible outcomes.

Subject of Research: Advances in molecular imaging and radiopharmaceutical therapy reported in The Journal of Nuclear Medicine ahead-of-print research

Article Title: The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 11, 2026

Article References: The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 11, 2026. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: nuclear medicine, PET imaging, theranostics, radiopharmaceutical therapy, PSMA PET, neuroendocrine tumors, neuroblastoma, amyloid PET, prostate cancer, triple-negative breast cancer, kidney cancer, tumor-associated macrophages

To understand why METTL3 has attracted such intense scrutiny, it helps to start with the chemistry. N6-methyladenosine is the most abundant internal chemical modification found in messenger RNA across eukaryotic cells, and it is installed and removed dynamically by dedicated enzyme complexes. METTL3 functions as the chief catalytic subunit of the methyltransferase complex, working alongside METTL14, which provides structural support, and accessory factors such as WT1-associated protein, VIRMA/KIAA1429, RBM15 and ZC3H13, which help target the complex to specific RNA substrates. The review details METTL3’s modular architecture: a central methyltransferase domain that binds the universal methyl donor S-adenosylmethionine, a zinc finger domain and a leading helix that contribute to substrate recognition, and a nuclear localization signal that governs where in the cell the protein operates. This structural organization allows METTL3 to deposit methyl marks onto thousands of RNA transcripts, altering their stability, translation efficiency, splicing and export without changing the underlying genetic sequence.

Because m6A methylation acts post-transcriptionally, it gives cancer cells a rapid and reversible way to reprogram gene expression. The review documents how METTL3 expression is itself regulated by an array of upstream signals, including cigarette smoke condensate in lung cancers, lactylation of the histone mark H3K18 in pancreatic ductal adenocarcinoma, the transcription factor Yin-yang 1, the hepatitis B X-interacting protein in hepatoblastoma, and the peptidyl prolyl isomerase PIN1. Once elevated, METTL3 methylates transcripts encoding drivers of proliferation, invasion and metabolic adaptation in malignancies ranging from acute myeloid leukemia and chronic myeloid leukemia to pancreatic, colorectal, gastric and esophageal cancers, hepatocellular carcinoma, glioblastoma, bladder cancer, ovarian cancer, prostate cancer, osteosarcoma and lung adenocarcinoma. In leukemia in particular, pharmacological inhibition of METTL3 has emerged as an active therapeutic strategy, with experimental inhibitors demonstrating that the enzyme is a druggable target rather than an incidental marker.

The most consequential portion of the review, however, concerns tumor immune escape, the process by which malignant cells avoid recognition and destruction by cytotoxic T lymphocytes, natural killer cells and other immune effectors. The authors argue that METTL3 operates along two parallel routes. The first is intrinsic: within tumor cells, METTL3-mediated methylation of specific transcripts triggers metabolic reprogramming that changes what nutrients the tumor consumes and what metabolites it releases into its surroundings. In several cancer types, METTL3 upregulates glycolytic enzymes such as hexokinase 2, intensifying aerobic glycolysis and depleting glucose from the microenvironment while flooding it with lactate and other immunosuppressive metabolites. In hepatocellular carcinoma associated with non-alcoholic fatty liver disease, METTL3 has been linked through the SREBP cleavage activating protein to lipid metabolic shifts that further distort immune signaling. These metabolic alterations do more than feed the tumor; they create a biochemical landscape in which infiltrating lymphocytes struggle to maintain their effector functions.

The second route is extrinsic and centers on the functional remodeling of tumor-infiltrating immune cells themselves. The review synthesizes evidence that METTL3 activity in macrophages skews these cells toward a tumor-associated, pro-tumoral phenotype, in part by methylating transcripts tied to the complement receptor C5aR1 and other polarization regulators. In myeloid-derived suppressor cells, METTL3-dependent methylation enhances immunosuppressive output, including the catabolism that generates kynurenine, a metabolite that acts on the N-methyl-D-aspartate receptor and other targets to dampen T-cell responses. Dendritic cells, the professional antigen-presenting cells that ignite anti-tumor T-cell immunity, also fall under METTL3’s influence, with methylation of transcripts governing maturation and interferon signaling impairing their ability to present tumor-associated antigens. Even regulatory T cells, the immune system’s own brakes, appear subject to METTL3-controlled tuning, which can tilt the balance of the tumor immune microenvironment further toward suppression.

Immune checkpoint blockade, the class of therapies that includes antibodies against PD-1 and its ligand PD-L1, has transformed treatment for many cancers but fails in a majority of patients. The review makes the case that METTL3 is deeply entangled with this variability. In lung adenocarcinoma, METTL3-mediated methylation influences splicing factors such as serine-arginine protein kinase 1, affecting PD-L1 expression and thereby the tumor’s visibility to checkpoint inhibitors. In melanoma and other models, elevated METTL3 in tumor cells has been associated with reduced interferon-gamma responsiveness and diminished recruitment of cytotoxic T lymphocytes, whereas loss of METTL3 can restore inflammatory chemokine production and sensitize tumors to anti-PD-1 therapy. Conversely, METTL3 activity within T cells themselves regulates their differentiation, integrin beta 1-mediated trafficking, granzyme B production and persistence, meaning that the same enzyme can either undermine or support immunotherapy depending on which cell compartment is examined. This cell-type-specific duality, the authors emphasize, is precisely why a systems-level understanding of the METTL3 network is needed before the enzyme can be safely targeted in combination regimens.

The clinical dimension of the review extends to biomarker discovery. Across multiple tumor types, METTL3 expression profiles correlate with disease stage, immune infiltration patterns, immune checkpoint molecule abundance and patient survival, suggesting that METTL3 levels in tumor biopsies could one day help stratify patients for immunotherapy or identify those likely to experience hyperprogression. The authors also survey emerging therapeutic approaches beyond small-molecule catalytic inhibitors, including RNA-targeted strategies such as antisense oligonucleotides and targeted protein degradation, as well as rational combinations that pair METTL3 inhibition with immune checkpoint blockade, metabolic interventions or epigenetic drugs. The concept of topical immune modulation, in which RNA-modification biology is exploited to reprogram immune cells locally within the tumor, features among the forward-looking therapeutic ideas discussed.

Yet the review is equally candid about the gaps that remain. The complete molecular network connecting METTL3 to tumor immune escape has not been systematically mapped, and many of the individual methylated transcripts responsible for the phenotypes described above have been characterized only in isolation. It is not always clear whether METTL3’s effects on immunity are direct, mediated through methylation of immune-regulatory transcripts, or indirect, secondary to its influence on tumor metabolism and growth. Context dependence complicates the picture further: METTL3 appears to act as an oncogene in several cancers but has been reported to exert tumor-suppressive effects in others, and its activity in immune cells can either restrain or promote anti-tumor responses depending on the cell type and disease setting. Resolving these contradictions, the authors argue, will require single-cell multi-omics approaches that can trace m6A deposition, transcript output and immune phenotype simultaneously at cellular resolution in human tumors.

The overarching message is that METTL3 should be viewed as a critical molecular hub bridging the intrinsic properties of cancer cells and the immune responses of the surrounding microenvironment. As the most prevalent internal RNA modification in eukaryotes, m6A methylation offers tumors a fast, flexible and reversible layer of gene control, and METTL3 is the enzyme that wields it. Whether delivered as a standalone epitranscriptomic therapy or woven into combination strategies with checkpoint inhibitors and metabolic drugs, precise targeting of METTL3 represents a highly promising anti-tumor frontier. The authors caution that translating that promise into clinical benefit will depend on refined dissection of the regulatory network governing tumor immune escape and on the development of highly specific agents that can reach the right cells at the right time. For now, the review consolidates a rapidly growing literature into a coherent framework, positioning the RNA methyltransferase that was once studied as a matter of basic biochemistry at the center of the fight against cancer’s ability to hide.

Subject of Research: The role of the m6A RNA methyltransferase METTL3 in tumor immune escape and cancer treatment

Article Title: Methyltransferase-like 3: structure, biological function and role in tumor immune escape and treatment

Article References: Liu, G., Zhu, Y., Zhang, J., Wu, J., Liao, M., Zhao, J., Guo, M., & Xu, L. (2026). Methyltransferase-like 3: structure, biological function and role in tumor immune escape and treatment. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08960-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08960-y

Keywords: METTL3, m6A methylation, tumor immune escape, epitranscriptomics, RNA modification, tumor microenvironment, immune checkpoint blockade, metabolic reprogramming, immunotherapy, cancer epigenetics, tumor-associated macrophages, PD-L1

Tumor-associated macrophages and microglia collectively constitute one of the largest immune cell populations in glioblastoma, often accounting for up to a third of the total cellular mass of the tumor. Unlike the inflammatory macrophages that would normally sweep into tissue to destroy pathogens or clear damaged cells, macrophages residing inside glioblastomas adopt a profoundly tumor-supportive identity. They secrete growth factors that stimulate tumor cell proliferation, remodel the extracellular matrix in ways that ease invasion, suppress cytotoxic T cell activity, and blunt the effectiveness of immunotherapies that have transformed the treatment of many other cancers. Understanding where these macrophages come from, and what forces shape their immunosuppressive character, has therefore become a central question in neuro-oncology.

The prevailing view has long been that tumor-associated macrophages in the brain arise from two principal sources. The first is the resident microglia, the innate immune cells native to the central nervous system, which become corrupted by tumor-derived signals. The second is circulating monocytes, produced in the bone marrow, which are recruited across the disrupted blood-brain barrier and then differentiate into macrophages within the tumor microenvironment. The new study focuses on this second pathway and asks a deceptively simple question: what cellular intermediaries in the tumor decide that an incoming monocyte should become a macrophage, and what kind of macrophage it becomes?

The answer, the researchers report, involves a population of pericyte-like stromal cells that express fibroblast activation protein, a membrane-bound serine protease that has served for decades as a marker of activated fibroblasts in wound healing and in the desmoplastic stroma of many solid tumors. Pericytes are mural cells that normally wrap around blood vessel endothelial cells, stabilizing vasculature and helping to maintain the blood-brain barrier. In glioblastoma, however, the study indicates that a subset of these pericyte-like cells acquires FAP expression and, with it, a striking new function: the ability to promote the differentiation of monocytes into macrophages with a tumor-associated phenotype.

Technically, the investigators combined single-cell transcriptomic analysis with functional assays to dissect this interaction. Single-cell RNA sequencing allows researchers to profile the gene expression of thousands of individual cells within a tumor, revealing not only the identity of rare cell populations but also the signaling ligands and receptors they deploy. By mapping the communication networks among tumor cells, macrophages, and stromal compartments, the team was able to identify FAP-positive pericyte-like cells as a hub of immunomodulatory signaling. In co-culture experiments, these cells were shown to drive monocytes toward a macrophage fate, biasing the resulting cells toward the immunosuppressive, pro-tumoral polarization that characterizes tumor-associated macrophages in glioblastoma.

The clinical implications of this finding are considerable. Glioblastoma has proven stubbornly resistant to immune checkpoint inhibitors, the antibody therapies that unleash T cells against melanoma, lung cancer, and many other malignancies. One widely cited explanation is that the glioblastoma microenvironment is saturated with immunosuppressive macrophages and microglia that actively paralyze T cells. If FAP-positive pericyte-like cells are among the architects of this immunosuppressive army, then targeting them, or the signals they use to educate monocytes, could represent a way to thin the ranks of tumor-associated macrophages and thereby open a window for T cell-based immunotherapy to function.

Fibroblast activation protein itself is an appealing therapeutic target. It is minimally expressed in healthy adult tissues but abundant in activated stromal cells across multiple cancers, which has already made it the focus of antibody-drug conjugates, small-molecule inhibitors, and radioligand imaging agents in ongoing clinical trials elsewhere in oncology. The demonstration that FAP marks a functionally important stromal population within glioblastoma raises the possibility that strategies developed for pancreatic, breast, and colorectal cancers could be adapted to brain tumors, although the blood-brain barrier and the infiltrative nature of glioblastoma present formidable delivery challenges that any such approach would need to overcome.

Beyond therapy, the study adds an important conceptual layer to the evolving understanding of the glioblastoma microenvironment. Pericytes have traditionally been studied for their roles in vascular biology: they regulate capillary diameter, contribute to blood-brain barrier integrity, and scavenge cellular debris. The idea that a pericyte-derived population can act as an immune educator, converting myeloid precursors into tumor-promoting macrophages, underscores how fluid the functional boundaries are between the vascular, stromal, and immune compartments of a tumor. It also helps explain why glioblastomas are so consistently and comprehensively immunosuppressive: the tumor appears to recruit or reprogram multiple cell types, including structural cells of its own vasculature, into a coordinated anti-immune apparatus.

There remain important questions for future work. The precise molecular signals by which FAP-positive pericyte-like cells induce monocyte differentiation, whether through secreted cytokines such as colony-stimulating factors, direct cell-cell contact, or remodeling of the extracellular matrix, will determine which points in the pathway are most druggable. It will also be essential to establish how these cells are themselves generated, whether they represent a distinct developmental lineage or a pathological reprogramming of ordinary pericytes, and whether their abundance correlates with patient outcomes, treatment resistance, or response to emerging immunotherapies. Longitudinal studies in patient cohorts and validation in additional model systems will be needed to translate the mechanism into prognostic and therapeutic tools.

Nevertheless, the study offers a vivid illustration of how modern single-cell biology is dismantling the old picture of tumors as homogeneous masses of malignant cells. Glioblastoma emerges instead as an ecosystem, one in which tumor cells, immune cells, vascular cells, and stromal cells engage in continuous negotiation, with each population reshaping the others for the tumor’s benefit. Identifying FAP-positive pericyte-like cells as promoters of macrophage differentiation adds a new node to this ecosystem map, and with it, a new set of potential targets. For patients facing a disease with a median survival measured in months despite surgery, radiation, and chemotherapy, every new node represents a new opportunity, and this one connects two of the most immunologically important cell types in the tumor. The hope, shared across the field, is that disrupting this stromal-immune axis could finally give immunotherapy a foothold in one of medicine’s most stubborn cancers.

The distinction between microglia and monocyte-derived macrophages has become increasingly tractable in recent years thanks to advances in single-cell and fate-mapping techniques. Microglia carry a transcriptional signature shaped by their embryonic origin and lifelong residence in the central nervous system, while recruited macrophages retain markers of their bone marrow lineage. Being able to separate these populations reliably matters therapeutically, because the two compartments respond differently to environmental cues and may require different intervention strategies. The identification of a stromal intermediary that actively shapes the monocyte-derived arm adds a layer of specificity to this growing taxonomy.

Pericyte plasticity is itself an area of intense investigation. In models of tissue injury, pericytes can detach from vessels, adopt migratory and secretory behaviors, and participate in scar formation. Similar programs appear to be activated within tumors, where aberrant signaling from malignant cells and from the disrupted vasculature may push pericytes into states that diverge substantially from their physiological roles. The acquisition of fibroblast activation protein expression by pericyte-like cells in glioblastoma fits this broader pattern of stromal remodeling, suggesting that the tumor co-opts a wound-healing-like program for its own purposes.

It is also worth noting that the monocyte-to-macrophage transition is not a single step but a continuum, with intermediate cells that retain plasticity. Signals encountered during recruitment and early differentiation can lock in long-lasting epigenetic programs, meaning that brief exposure to stromal factors may have durable consequences for macrophage behavior. This temporal sensitivity creates potential intervention windows: if the educational signal from FAP-positive cells can be interrupted early, the resulting macrophages might never adopt their tumor-supportive identity.

Finally, the convergence of stromal biology and immunology reflected in this work mirrors a trend across oncology, where cancer-associated fibroblasts and other stromal elements are increasingly recognized as active participants in immune evasion rather than passive scaffolding, reinforcing the case for combination approaches that target both malignant and stromal compartments.

Subject of Research: FAP-positive pericyte-like cells promoting monocyte differentiation into tumor-associated macrophages in glioblastoma

Article Title: FAP+ pericyte-like cells promote monocyte differentiation into tumor-associated macrophages in glioblastoma

Article References: Houdova Megova, M., Shard, C., Vymolova, B., Ternerova, N., Svablova, T., Buna, T., Straka, D., Vanickova, Z., Krepela, E., Kupcova Skalnikova, H., Kolar, M., Sachova, J., Kubovciak, J., Balaziova, E., Vymola, P., Hrabal, P., Ebert, L. M., Patil, A., Tomas, R., … Sedo, A. (2026). FAP+ pericyte-like cells promote monocyte differentiation into tumor-associated macrophages in glioblastoma. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01827-8

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01827-8

Keywords: glioblastoma, tumor-associated macrophages, pericytes, FAP, monocytes, tumor microenvironment, immunosuppression, single-cell sequencing, immunotherapy, neuro-oncology, pericyte-like, cells

The molecular logic of this process begins within hours of the first radiation fraction. Ionizing radiation shatters genomic DNA in surviving tumor cells and simultaneously generates an overwhelming burst of intracellular reactive oxygen species. These two stress signals converge on the CCL2 promoter through parallel transcriptional highways. Along the first route, DNA double-strand breaks activate the ataxia-telangiectasia mutated kinase, ATM, which phosphorylates and partners with nuclear factor-kappa-B essential modulator, NEMO. This complex migrates to the cytoplasm, activates the IκB kinase machinery, and liberates the transcription factor NF-κB, which then returns to the nucleus and binds κB sites on the CCL2 promoter. Along the second route, radiation-generated ROS inhibit protein tyrosine phosphatases, releasing the brakes on JAK2 and Src kinases and sustaining activation of STAT3, while also firing the JNK and p38 mitogen-activated protein kinase cascades that stimulate the AP-1 complex. Because the CCL2 promoter carries binding sites for NF-κB, STAT3 and AP-1, these pathways do not act independently but converge synergistically, and together with recruited histone acetyltransferases such as p300/CBP they drive CCL2 transcription to remarkable heights even after the radiation beam is switched off.

Critically, the review emphasizes that surviving tumor cells are not the only source of this chemokine flood. In treatment-naïve tumors, CCL2 is held at basal levels sufficient for tissue homeostasis, but radiation abruptly disrupts this equilibrium and provokes what the authors describe as a chemokine storm. Radiation drives stromal fibroblasts into irreversible proliferative arrest, a state known as cellular senescence, which activates the senescence-associated secretory phenotype. Cancer-associated fibroblasts emerging from this program become exceptionally stable and durable factories of CCL2, sustaining elevated concentrations long after the acute phase of treatment and playing a predominant role in the late phases of microenvironmental remodeling. Radiation-damaged endothelial cells add to the chorus by upregulating CCL2 and adhesion molecules along the vasculature, establishing the physical prerequisite for early myeloid infiltration, while monocytes recruited into the hypoxic, fibrotic microenvironment themselves differentiate into macrophages that secrete additional CCL2. This creates a self-amplifying positive feedback loop in which macrophages recruit more macrophages, serving as the primary driver of persistent, late-stage secretion.

The dominant cellular source of CCL2 after irradiation is not fixed but context dependent, shaped by tumor lineage, stromal composition, hypoxia and intercellular communication. In glioblastoma, where microglia, macrophages and astrocytes constitute major stromal populations, CCL2 may be produced mainly by tumor cells and macrophages. In contrast, in tumors with dense mesenchymal stroma, such as breast and pancreatic cancers, cancer-associated fibroblasts may represent the dominant and most durable source. These producing populations do not act independently: in colorectal cancer models, direct contact between fibroblasts and recruited macrophages enhanced CCL2 secretion by both cell types, with macrophage CCL2 expression boosted by as much as forty-fold, underscoring the network nature of the response rather than a simple one-way relay from tumor cell to immune cell.

Once CCL2 spills into the circulation, it acts far beyond the irradiated field, reaching the bone marrow and spleen and triggering the massive egress of CCR2-expressing inflammatory monocytes into the bloodstream. Guided by the chemotactic gradient, these cells transmigrate across the radiation-damaged vascular endothelium and flood the tumor bed, where they undergo deep transcriptional reprogramming. CCL2 binding to CCR2, a classical G protein-coupled receptor, activates PI3K/Akt and MAPK/ERK survival pathways alongside JAK/STAT3, while the hypoxic, debris-laden microenvironment and its abundant transforming growth factor-beta steer the newcomers toward an M2-like, immunosuppressive macrophage fate marked by CD163 and arginase-1 expression. These tumor-associated macrophages then suppress antigen presentation by downregulating MHC-II and co-stimulatory molecules on dendritic cells, induce regulatory T cell proliferation, and release epidermal growth factor and vascular endothelial growth factor that nourish residual tumor cells. The review notes that the familiar M1/M2 dichotomy is an oversimplification, with single-cell sequencing revealing a continuum of macrophage states whose spatial positioning relative to vessels, stroma and excluded T cells shapes their pathological impact.

Monocytic myeloid-derived suppressor cells represent a second arm of this myeloid invasion. Local CCL2 concentrations after radiotherapy correlate strongly with intratumoral enrichment of these cells, and pharmacological CCR2 blockade with monoclonal antibodies or small molecules significantly impairs their infiltration. Once embedded in the tumor, MDSCs construct what the review describes as a biochemical barrier. Under STAT3 transactivation they upregulate arginase-1, which depletes local L-arginine, starving T cells of an amino acid required for CD3ζ chain expression and arresting their cell cycle at the G0/G1 boundary. Concurrently, inducible nitric oxide synthase generates nitric oxide that reacts with superoxide to form reactive nitrogen species, which nitrate tyrosine residues within the T cell receptor complex. The result is a recognition failure so profound that T cells can no longer identify tumor neoantigens, including those released during radiation-induced immunogenic cell death. Even if cytotoxic T cells physically reach the tumor, they arrive functionally exhausted and paralyzed, a phenomenon the authors argue elegantly explains why radiotherapy alone so often fails to elicit durable systemic immunity.

Beyond these cellular mechanisms, the CCL2/CCR2 axis drives physical remodeling that locks T cells out of the tumor entirely. Recruited macrophages engage in bidirectional cross-talk with cancer-associated fibroblasts, stimulating them through TGF-beta and platelet-derived growth factor to deposit dense type I collagen and highly polymerized hyaluronan. This aberrant desmoplasia forms a fibrotic wall that strands effector T cells in the peritumoral stroma, preventing their penetration into the tumor nest. Simultaneously, macrophage-derived matrix metalloproteinases proteolytically degrade the CXCL9 and CXCL10 chemokines that normally guide T cell trafficking, while TAM-secreted CCL20 and CCL22 recruit regulatory T cells that further entrench immunosuppression. The microenvironment thus transitions from an immune-inflamed state toward an immune-excluded or immune-desert phenotype in which radiation-induced antigen release cannot be converted into tumor killing.

The review also highlights how vascular remodeling compounds the problem. High-dose irradiation damages tumor vasculature and induces profound hypoxia, stabilizing hypoxia-inducible factor-1 alpha, which itself upregulates CCL2 and reinforces a positive feedback loop. Monocytes drawn into this hypoxic milieu differentiate into pro-angiogenic subpopulations, including Tie2-expressing macrophages, that become the principal sources of VEGF-A and MMP-9. The ensuing microvascular rebound provides residual tumor cells with nutrient supply and survival conduits within days to weeks of treatment, while a parallel pro-fibrotic cascade lays the groundwork for late-stage radiation-induced fibrosis. Together, abnormal angiogenesis, stromal stiffening and matrix deposition form an interlocking set of barriers that the authors summarize as biochemical, physical and vascular obstacles to effective immunity.

Notably, the immunological consequences of radiation are schedule dependent. Conventional fractionated radiotherapy at roughly 1.8 to 2.0 Gy per day inflicts chronic sublethal stress that pushes cells into senescence, sustaining ATM/NEMO/NF-κB signaling and a stable senescence-associated secretory phenotype in which CCL2 climbs steadily to an unremitting plateau. Ablative stereotactic body radiotherapy, by contrast, triggers massive acute cell death and a burst-like CCL2 surge that rapidly mobilizes Ly6C-positive inflammatory monocytes and drives pro-angiogenic macrophage differentiation. Dose also dictates the fate of competing immunostimulatory signals: moderate fractions of 8 to 10 Gy promote cytosolic DNA accumulation that activates the cGAS/STING pathway and type I interferon signaling, enhancing the CXCL9/10–CXCR3 axis and CD8-positive T cell infiltration. However, single fractions exceeding roughly 12 to 18 Gy induce the exonuclease TREX1, which degrades cytosolic DNA and silences this interferon response, leaving CCL2-driven myeloid recruitment relatively dominant and potentially explaining immunosuppression and recurrence after high-dose regimens.

Translating these insights into therapies has proven difficult. Early-phase clinical trials of carlumab, a monoclonal antibody against CCL2, in solid tumors and metastatic castration-resistant prostate cancer delivered underwhelming results, largely due to two compensatory mechanisms. First, neutralizing antibodies act as a sponge, binding free CCL2 and storing it in the circulation; when antibody levels decline, stored ligand is released in a dramatic rebound that can paradoxically accelerate tumor recurrence. Second, the microenvironment adapts through bypass signaling: when CCR2 blockade prevents monocytic infiltration, tumor cells upregulate CXCL1/2/5/8 and recruit polymorphonuclear MDSCs via CXCR2, preserving immunosuppression through substitute cells. These failures, the review argues, do not negate the axis’s value but signal that CCL2/CCR2 targeting is best deployed in rational combinations rather than as monotherapy.

The most promising framework is a triplet strategy integrating radiotherapy, CCR2 inhibition and immune checkpoint inhibitors, in which each component addresses a distinct layer of resistance. Radiation serves as an in situ vaccine, releasing tumor antigens and danger signals that prime dendritic cells and T cell responses. CCR2 inhibitors intercept the chemokine surge, preventing macrophages and MDSCs from constructing immunosuppressive barriers and allowing effector T cells to infiltrate. PD-1/PD-L1 antibodies then reverse exhaustion in the T cells that finally reach the tumor nest. Preclinical evidence supports this logic: CCR2/CCR5 inhibition permitted radiation-induced effector T cell infiltration in pancreatic cancer models, and dual CCR2/CXCR2 blockade improved chemotherapy responses by simultaneously restricting macrophage and neutrophil recruitment. The authors caution that clinical evidence for the full triplet remains limited and emphasize three priorities for translation: biomarker-driven patient stratification using dynamic blood CCL2 levels and CCR2-positive myeloid infiltration patterns; precise timing of CCR2 antagonists within the 24 to 48 hour window of peak chemokine release; and multi-target regimens combining CCR2 with CXCR2 or CSF-1R inhibitors to outflank compensatory networks. If these dimensions are mastered, the review concludes, targeting the CCL2/CCR2 axis could dismantle the barriers that currently confine radiotherapy’s promise, transforming it from a local cytotoxic tool into a genuine in situ vaccine capable of kindling durable, systemic antitumor immune memory.

Subject of Research: The role of the CCL2/CCR2 chemokine signaling axis in radiation-induced immunosuppression, tumor microenvironment remodeling, and radioresistance.

Article Title: The CCL2/CCR2 axis in irradiated tumors: orchestrating immune recruitment and microenvironment remodeling

Article References: Li, B., Li, D., Liu, Q., & Ma, L. (2026). The CCL2/CCR2 axis in irradiated tumors: orchestrating immune recruitment and microenvironment remodeling. Clinical Cancer Bulletin, 5(1), Article 15. https://doi.org/10.1007/s44272-026-00069-z

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00069-z

Keywords: radiotherapy, CCL2/CCR2 axis, tumor microenvironment, tumor-associated macrophages, myeloid-derived suppressor cells, immunosuppression, radioresistance, cancer-associated fibroblasts, immune checkpoint inhibitors, radiation-induced fibrosis, immunotherapy, cGAS/STING

TAMs are not a single, uniform cell type. They occupy a spectrum of functional states shaped by cytokines, metabolites, oxygen levels, acidity, mechanical forces and signals released by cancer and stromal cells. At one end are M1-like macrophages, which respond to inflammatory cues such as interferon-γ and tumor necrosis factor-α. Through pathways including JAK–STAT1, NF-κB and IRF5, these cells increase production of inflammatory mediators, nitric oxide and antigen-presentation machinery. They can help recruit CD8-positive cytotoxic T cells and natural killer cells. At the other end are M2-like programs, promoted by interleukins 4, 10 and 13, transforming growth factor-β and colony-stimulating factor 1. Signaling through STAT3, STAT6, PPARγ and PI3K–AKT–mTOR drives tissue repair, blood-vessel growth and immune suppression. In real tumors, macrophages rarely fit neatly into either category, but the M1/M2 framework remains useful for describing opposing immune functions.

The cancer-promoting side of this plasticity is extensive. M2-like TAMs can release epidermal growth factor, transforming growth factor-β and platelet-derived growth factor, supporting tumor-cell survival and proliferation. They produce matrix metalloproteinases and cathepsins that break down collagen and basement membranes, opening routes for invasion. They also secrete vascular endothelial growth factor, basic fibroblast growth factor and interleukin-8, encouraging the formation of abnormal blood vessels that feed the tumor and provide escape routes for metastasizing cells. Meanwhile, interleukin-10, transforming growth factor-β, PD-L1 and other suppressive signals blunt cytotoxic T cells and natural killer cells while attracting regulatory T cells and myeloid-derived suppressor cells. TAMs can even help maintain cancer stem-cell niches and interact with nerves, creating feedback loops that reinforce malignancy. Reprogramming them could therefore remodel immunity, blood vessels, extracellular matrix and tumor metabolism at the same time.

That possibility is especially attractive because tumors are difficult places for conventional drugs to reach. Dense stromal tissue, abnormal vasculature, low oxygen, acidic pH and high interstitial pressure can prevent therapeutic molecules from distributing evenly. Systemic cytokines, gene therapies and macrophage-directed drugs may also affect healthy tissues or lose effectiveness as tumors adapt. Physical stimulation offers a different mode of access: energy can be focused or applied repeatedly, with variables such as intensity, frequency, wavelength, pulse duration and temperature adjusted to the target. The review describes this as a controllable interface between engineering and immunology. Mechanical stress may open ion channels; light can excite sensitizers or alter redox chemistry; electric fields can change membrane permeability; magnetic particles can generate heat or release iron; and radiation can provoke immunogenic cell death. These inputs ultimately converge on the same inflammatory networks that govern macrophage behavior.

Light-based therapies illustrate both the promise and the engineering challenge. Photodynamic therapy activates a photosensitizer to generate reactive oxygen species, damaging tumor cells and inducing immunogenic cell death. That process can expose calreticulin, release ATP and liberate HMGB1, danger signals that alert dendritic cells and macrophages. Conventional type II photodynamic therapy depends heavily on molecular oxygen, making it vulnerable to the severe hypoxia found in solid tumors. Newer type I systems generate radicals such as superoxide and hydroxyl radicals under oxygen-poor conditions, while some nanoplatforms produce oxygen from hydrogen peroxide in the tumor. Type III photosensitizers aim to work without oxygen by transferring excitation energy directly to biomolecules such as RNA. Photothermal therapy takes another route, converting near-infrared light into heat. High temperatures can rapidly ablate tissue but risk collateral damage; mild heating around 42–45°C may instead improve perfusion, relieve hypoxia and activate NF-κB and STAT1-linked inflammatory programs. The trade-off is that heat-shock proteins can protect tumor cells, prompting efforts to inhibit HSP70 during treatment.

Ultrasound may be particularly useful for tumors buried deep within the body because acoustic energy can penetrate tissue and be focused under imaging guidance. High-intensity focused ultrasound can destroy tumor tissue through heat, releasing tumor antigens and heat-shock proteins that stimulate adaptive immunity. Mechanical forms of focused ultrasound, including histotripsy, use pressure waves and cavitation—the formation and collapse of microscopic bubbles—to fragment tissue while limiting thermal buildup. The resulting release of calreticulin and HMGB1 can push macrophages toward inflammatory activity. Yet the immune effect depends on the amount of tissue disrupted: very small ablation volumes may not provide enough antigenic material to overcome suppression, making combination with immune checkpoint blockade important. Ultrasound-targeted microbubble destruction offers a different mechanism. Cavitating microbubbles temporarily disturb blood-vessel walls and cell membranes, increasing vascular permeability and potentially altering macrophage recruitment. Sonodynamic therapy uses ultrasound to activate sensitizers and generate reactive oxygen species, pairing deep-tissue access with oxidative tumor injury. Its major obstacle remains hypoxia, which has spurred the development of oxygen-generating particles and systems that consume tumor lactate.

Electrical stimulation connects tumor treatment to the electrophysiology of immune cells. Nanosecond pulsed stimulation delivers extremely brief, intense electric pulses that create transient nanopores in cell and organelle membranes. The resulting calcium flux, endoplasmic-reticulum stress and reactive oxygen production can induce immunogenic cell death and activate inflammatory circuits such as cGAS–STING. Preclinical studies described in the review associate this approach with depletion of M2-like macrophages, increased M1-like activity and reductions in regulatory T cells and suppressor cells. Tumor-treating fields use much gentler alternating fields—roughly 1–3 volts per centimeter at 100–300 kilohertz—to disrupt cancer-cell division. Their immune effects appear to arise partly because dying tumor cells release danger signals that activate macrophages through NF-κB and MAPK pathways, although direct in vivo evidence for macrophage reprogramming remains limited. Piezoelectric materials could provide a wireless alternative: ultrasound mechanically deforms a material such as β-phase polyvinylidene fluoride, generating a local electric potential. That signal can open voltage-gated calcium channels and activate a calcium–CAMK2A–NF-κB axis, while some piezoelectric materials also catalyze reactive oxygen species.

Magnetic approaches offer deep penetration without requiring an external beam to pass through the entire tumor. Magnetic nanoparticles can convert an alternating magnetic field into localized heat, a process known as magnetic hyperthermia. Mild heating between about 39 and 45°C may release danger signals from tumor cells while also improving the inflammatory environment. At the same time, acidic tumor conditions or lysosomal processing can release iron ions from particles. Through Fenton and Fenton-like reactions, iron catalyzes the formation of highly reactive hydroxyl radicals, which can damage cancer cells and act as redox signals that favor M1-like macrophage programs. Some particles may influence macrophages without meaningful heating by disturbing iron homeostasis directly, although those effects depend strongly on size, shape, surface chemistry and intracellular dissolution. Radiation adds a clinically established but dose-sensitive option. Moderate doses of roughly 2–10 gray can increase inflammatory macrophage markers through HMGB1, ROS, ATM kinase and NF-κB signaling. Higher doses may worsen hypoxia and activate the HIF-1α–SDF-1–CXCR4 pathway, drawing in immunosuppressive macrophages instead. Ultra-high-dose-rate FLASH radiation has shown a more favorable M1/M2 balance in preclinical work, but the optimal dose, fractionation and treatment sequence remain unresolved.

The review’s central message is not that one form of energy is destined to replace immunotherapy, but that physical stimulation could make immune treatments more precise and more effective. Each modality has a different clinical niche: light is naturally suited to superficial or endoluminal lesions; focused ultrasound can reach deep targets; electrical fields are attractive where electrodes or transducer arrays can be positioned; magnetic systems can act remotely but generally require reliable nanoparticle deposition; and radiotherapy already has established planning and delivery infrastructure. The field is still dominated by laboratory and animal studies, and macrophage polarization is highly dependent on tissue context and stimulation parameters. A treatment that promotes inflammation in one tumor could produce tolerance or immunosuppression in another if the dose, timing, oxygen level or metabolic state is different. Future progress will require standardized energy dosimetry, imaging-guided delivery, spatial and single-cell immune profiling, and careful monitoring of normal-tissue injury. If those hurdles can be overcome, externally controlled energy may offer a powerful way to turn the tumor’s most adaptable immune residents against the cancer they have been helping to protect.

The discovery adds to growing evidence that the genome contains many functional peptides hidden within RNA molecules annotated as long noncoding RNAs. Long noncoding RNAs, or lncRNAs, are generally defined as transcripts longer than 200 nucleotides that do not serve as conventional templates for large proteins. Increasingly, however, scientists have found that some lncRNAs contain short open reading frames capable of producing micropeptides. These molecules can be only a few dozen or a few hundred amino acids long, yet they may regulate signaling complexes, membrane processes and gene expression. In this case, the researchers traced an immune-suppressive activity associated with the lncRNA gene USP30-AS1 to a peptide encoded within it. They designated the peptide USP30-AS1-encoded immune suppressor, abbreviated UEIS.

UEIS was found to be highly expressed in tumor-associated macrophages, immune cells that accumulate within cancers and can be reprogrammed by the tumor microenvironment. Macrophages are highly adaptable: depending on the signals they receive, they can support inflammation and attack abnormal cells, or promote tissue repair, blood-vessel formation and tumor growth. In the cancer setting, tumor-associated macrophages frequently acquire a protumorigenic state. Rather than efficiently supporting cytotoxic lymphocytes, they can help create an immune-permissive environment in which malignant cells survive, invade surrounding tissue and resist therapy. According to the study, UEIS contributes to this transition by suppressing macrophage interferon responses and thereby reducing the conditions needed for effective antitumor T cell activity.

The pathway targeted by UEIS normally functions as an intracellular alarm system for abnormal DNA. When tumor-derived DNA reaches the cell cytoplasm, it can be detected by the enzyme cGAS, which synthesizes the signaling molecule cyclic GMP–AMP. This molecule activates the adaptor protein STING, initiating a cascade involving the kinase TBK1 and downstream transcription factors that stimulate production of type I interferons. These interferons, including interferon-beta and related molecules, can strengthen antigen presentation, activate innate immune cells and help recruit and sustain T cells capable of attacking cancer. The pathway is therefore considered one of the most important bridges between the detection of tumor-associated DNA and the development of antitumor immunity.

The researchers found that UEIS is not simply present in macrophages at a constant level. Instead, it is induced after tumoral DNA activates the cGAS–STING pathway, but it appears relatively late in the response. This timing suggests that UEIS acts as a negative-feedback regulator. Early pathway activation can generate an interferon response, while later production of UEIS helps dampen that signal. Such feedback mechanisms are common in immune biology because uncontrolled interferon signaling can damage healthy tissue and trigger excessive inflammation. Cancer, however, may exploit this protective brake. By increasing UEIS after the initial alarm has sounded, tumor-associated macrophages can limit the duration or intensity of the immune response before it becomes sufficiently strong to support sustained tumor destruction.

At the molecular level, the study links UEIS to the formation of biomolecular condensates involving TBK1. Condensates are dynamic, membrane-free assemblies in which proteins and nucleic acids concentrate through multivalent interactions. They are increasingly recognized as organizing centers for signaling reactions, allowing pathway components to gather in the correct place and at the appropriate time. The researchers report that UEIS forms condensates with TBK1 and, through this interaction, interferes with the kinase’s association with STING. Because STING must engage TBK1 to efficiently transmit the signal generated by cytoplasmic DNA, disrupting that interaction effectively weakens the pathway downstream of DNA sensing. The result is reduced type I interferon signaling in macrophages.

The architecture of UEIS was also important to its activity. Experiments indicated that both an intrinsically disordered region and an alpha helix located at the extreme N terminus of the micropeptide were required for its function. Intrinsically disordered regions lack a single rigid three-dimensional structure and often enable flexible, multivalent interactions with several partners. They can be particularly important in the formation of biomolecular condensates because they provide repeated or adaptable binding surfaces. Alpha helices, by contrast, are structured elements that can create defined contact points within protein complexes. The findings suggest that UEIS may use its disordered region to support condensation while relying on its N-terminal helix to engage a signaling partner such as TBK1, although the precise atomic structure of the complex remains to be determined.

The therapeutic implications were tested with a peptide designed to disrupt UEIS–TBK1 condensation. Rather than attempting to eliminate the lncRNA or broadly inhibit the interferon pathway, the strategy focused on the physical interaction that gives UEIS its suppressive activity. The researchers report that the disrupting peptide inhibited UEIS function in tumor-associated macrophages. In experimental cancer models, treatment was associated with reduced tumor growth and a stronger response to immune checkpoint blockade. These results are significant because checkpoint inhibitors depend on an immune system capable of recognizing and attacking tumor cells. If macrophages suppress interferon signaling and maintain an immunosuppressive environment, blocking checkpoints alone may not be enough. Interrupting UEIS activity could help convert that environment into one more permissive for T cell function.

The findings position UEIS as a potential therapeutic target at the intersection of innate sensing, macrophage biology and cancer immunotherapy. They also illustrate why the search for cancer regulators cannot be limited to conventional protein-coding genes. A transcript previously categorized as noncoding can produce a short peptide that reorganizes a signaling pathway and changes the behavior of immune cells within tumors. Before the approach can be considered for clinical use, important questions will need to be addressed, including how selectively UEIS is expressed across cancers and normal tissues, whether disrupting its condensates causes unwanted inflammation, and how effectively the peptide can reach macrophages in human tumors. Nevertheless, the study offers a new explanation for how tumors attenuate cGAS–STING–type I interferon signaling and provides a possible way to strengthen immune checkpoint therapy by targeting a molecular brake embedded within a lncRNA.

Subject of Research: A micropeptide encoded by the lncRNA USP30-AS1 that suppresses cGAS–STING–type I interferon signaling in tumor-associated macrophages and promotes tumor growth.

Article Title: A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages.

Article References: Wang, X., Zhang, Y., Ma, J. et al. “A micropeptide encoded by the lncRNA USP30-AS1 promotes tumor growth by attenuating cGAS–STING–type I IFN signaling in macrophages.” Nature Cancer 7, 1047–1063 (2026). https://doi.org/10.1038/s43018-026-01195-2

Image Credits: AI Generated

DOI: July 2026

Keywords: UEIS, USP30-AS1, micropeptide, long noncoding RNA, tumor-associated macrophages, cGAS–STING signaling, type I interferon, TBK1, biomolecular condensates, immune checkpoint blockade, cancer immunotherapy.